Systemic Lupus Erythematosus (SLE) Drugs Market Report

Global and Region Systemic Lupus Erythematosus (SLE) Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：173
  • REPORT CODE：GMM1003665
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.

    Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.

    The report details the trend, potential and market size of Systemic Lupus Erythematosus (SLE) Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Systemic Lupus Erythematosus (SLE) Drugsmarket, defines the market attractiveness level of Systemic Lupus Erythematosus (SLE) Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Systemic Lupus Erythematosus (SLE) Drugs industry, describes the types of Systemic Lupus Erythematosus (SLE) Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Systemic Lupus Erythematosus (SLE) Drugs market and the development prospects and opportunities of Systemic Lupus Erythematosus (SLE) Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Systemic Lupus Erythematosus (SLE) Drugs market in Chapter 13.

    By Player:

    • Anthera Pharmaceuticals

    • Johnson & Johnson

    • GSK

    • ImmuPharma

    By Type:

    • Corticosteroids

    • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

    • Anti-Inflammatories

    • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

    • Antimalarials

    • BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)

    • Immunosuppressive Agents/Immune Modulators

    • Anticoagulants

    By End-User:

    • Intravenous

    • Sub-Cutaneous

    • Oral

    • Topical

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Systemic Lupus Erythematosus (SLE) Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Systemic Lupus Erythematosus (SLE) Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Systemic Lupus Erythematosus (SLE) Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Systemic Lupus Erythematosus (SLE) Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    • 7.2 United States Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    • 7.3 Europe Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    • 7.4 China Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    • 7.5 Japan Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    • 7.6 India Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    • 7.7 South Korea Systemic Lupus Erythematosus (SLE) Drugs Consumption (2017-2022)

    8 Region and Country-wise Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    • 8.4 China Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    • 8.6 India Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast (2022-2028)

    9 Global Systemic Lupus Erythematosus (SLE) Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Corticosteroids Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Anti-Inflammatories Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Antimalarials Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS) Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Immunosuppressive Agents/Immune Modulators Consumption and Growth Rate (2017-2022)

      • 9.1.8 Global Anticoagulants Consumption and Growth Rate (2017-2022)

    • 9.2 Global Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Intravenous Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Sub-Cutaneous Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Oral Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Topical Consumption and Growth Rate (2017-2022)

    10 Global Systemic Lupus Erythematosus (SLE) Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Anti-Inflammatories Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Antimalarials Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.7 Global Immunosuppressive Agents/Immune Modulators Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.8 Global Anticoagulants Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Intravenous Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Sub-Cutaneous Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Oral Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Topical Consumption Forecast and Growth Rate (2022-2028)

    11 Global Systemic Lupus Erythematosus (SLE) Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Systemic Lupus Erythematosus (SLE) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Systemic Lupus Erythematosus (SLE) Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Systemic Lupus Erythematosus (SLE) Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Systemic Lupus Erythematosus (SLE) Drugs Market Competitive Analysis

    • 14.1 Anthera Pharmaceuticals

      • 14.1.1 Anthera Pharmaceuticals Company Details

      • 14.1.2 Anthera Pharmaceuticals Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Anthera Pharmaceuticals Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    • 14.2 Johnson & Johnson

      • 14.2.1 Johnson & Johnson Company Details

      • 14.2.2 Johnson & Johnson Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Johnson & Johnson Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    • 14.3 GSK

      • 14.3.1 GSK Company Details

      • 14.3.2 GSK Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 GSK Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    • 14.4 ImmuPharma

      • 14.4.1 ImmuPharma Company Details

      • 14.4.2 ImmuPharma Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 ImmuPharma Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Systemic Lupus Erythematosus (SLE) Drugs

    • Figure Systemic Lupus Erythematosus (SLE) Drugs Picture

    • Table Global Systemic Lupus Erythematosus (SLE) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Systemic Lupus Erythematosus (SLE) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Systemic Lupus Erythematosus (SLE) Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Systemic Lupus Erythematosus (SLE) Drugs Consumption by Country (2017-2022)

    • Figure United States Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Systemic Lupus Erythematosus (SLE) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Systemic Lupus Erythematosus (SLE) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Corticosteroids Consumption and Growth Rate (2017-2022)

    • Figure Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Consumption and Growth Rate (2017-2022)

    • Figure Global Anti-Inflammatories Consumption and Growth Rate (2017-2022)

    • Figure Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Consumption and Growth Rate (2017-2022)

    • Figure Global Antimalarials Consumption and Growth Rate (2017-2022)

    • Figure Global BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS) Consumption and Growth Rate (2017-2022)

    • Figure Global Immunosuppressive Agents/Immune Modulators Consumption and Growth Rate (2017-2022)

    • Figure Global Anticoagulants Consumption and Growth Rate (2017-2022)

    • Figure Global Intravenous Consumption and Growth Rate (2017-2022)

    • Figure Global Sub-Cutaneous Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Consumption and Growth Rate (2017-2022)

    • Figure Global Topical Consumption and Growth Rate (2017-2022)

    • Figure Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anti-Inflammatories Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Antimalarials Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunosuppressive Agents/Immune Modulators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anticoagulants Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Intravenous Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Sub-Cutaneous Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Topical Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Systemic Lupus Erythematosus (SLE) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Systemic Lupus Erythematosus (SLE) Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Anthera Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Anthera Pharmaceuticals Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Anthera Pharmaceuticals Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    • Table GSK (Foundation Year, Company Profile and etc.)

    • Table GSK Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Systemic Lupus Erythematosus (SLE) Drugs Product and Service

    • Table ImmuPharma (Foundation Year, Company Profile and etc.)

    • Table ImmuPharma Systemic Lupus Erythematosus (SLE) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table ImmuPharma Systemic Lupus Erythematosus (SLE) Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US